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Context: Previous case reports associated prepubertal gynecomastia with lavender-containing
fragrances, but there appear to be no reports of premature thelarche.
Objective: To add to a case series about lavender-fragranced product use and breast growth in
children and to measure endocrine-disrupting chemical activity of essential oil components.
Design, Setting, and Patients: Patients experiencing premature thelarche or prepubertal gy-
necomastia with continuous exposure to lavender-fragranced products were evaluated in the
pediatric endocrinology departments of two institutions. Mechanistic in vitro experiments using
eight components of lavender and other essential oils were performed at National Institute of
Environmental Health Sciences.
Main Outcome Measures: Case reports and in vitro estrogen and androgen receptor gene ex-
pression activities in human cell lines with essential oils.
Results: Three prepubertal girls and one boywith clinical evidence of estrogenic action and a history
of continuous exposure to lavender-containing fragrances were studied. Breast growth dissipated
in all patients with discontinuation of the fragranced products. Some of the components tested
elicited estrogenic and antiandrogenic properties of varying degrees.
Conclusion: We report cases of premature thelarche that resolved upon cessation of lavender-
containing fragrance exposure commonly used in Hispanic communities. The precise developmental
basis for such conditions could be multifactorial. In vitro demonstration of estrogenic and
antiandrogenic properties of essential oil components suggests essential oils in these cases
could be considered a possible source and supports a possible link with idiopathic prepubertal
breast development. Whether the level of lavender oil estrogenic potency is sufficient to cause
these effects is unknown. (J Clin Endocrinol Metab 104: 5393–5405, 2019)
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Copyright © 2019 Endocrine Society
Received 5 September 2018. Accepted 2 August 2019.
First Published Online 8 August 2019
Abbreviations: 4-Terp, 4-terpineol; AR, androgen receptor; BPA, bisphenol A; CTSD,
cathepsin D; CYP4F8, cytochrome P450 family 4 subfamily F member 8; Di/Lim,
dipentene/limonene; DMSO, dimethyl sulfoxide; E2, estradiol; EDC, endocrine-disrupting
chemical; ERa, estrogen receptor a; ERE, estrogen response element; EUC, eucalyptol;
FBS, fetal bovine serum; Flut, flutamide; GREB1, growth regulation by estrogen in breast
cancer 1; ICI, fulvestrant/ICI 182,780; ISO, International Organization for Standardization;
LBD, ligand-binding domain; Lin, linalool; LinA, linalyl acetate; LO, lavender oil; LO-C,
lavender oil component; MMTV, mouse mammary tumor virus; NR, nuclear receptor;
PGR, progesterone receptor; SEC14L2, SEC14-like lipid binding 2; sFBS, stripped fetal
bovine serum; SRC, steroid receptor coactivator; TTO, tea tree oil; TTO-C, tea tree oil
component; a-Terp, a-terpinene; a-Terpl, a-terpineol; g-Terp, g-terpinene; UGT2B28,
UDP glucuronosyltransferase family 2 member B28.
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Mammary gland breast growth has been documentedas an estrogen receptor a (ERa)-dependent re-
sponse in experimental models (1) and clinical cases
(2). Although breast tissue primarily is thought of as a
female-specific end point, men also possess breast tissue
(3). Premature thelarche, defined as isolated breast
development without other signs of puberty before 8
years of age, is the most common pubertal disorder in
girls (4). The causes of this condition remain unclear
(5). On the other hand, transient thelarche has been
studied longitudinally no earlier than from 8 years of
age (6). Gynecomastia is a common clinical condition
that involves benign development of breast tissue in
men (3), but prepubertal gynecomastia is a relatively
rare condition (7, 8) and most cases are of unknown
cause (3).
Gynecomastia is suspected to have many etiologies.
Selected drugs and environmental exposures such as
alcohol, heroin, marijuana, amphetamines, antiulcer
medications, antibiotics (e.g., isoniazid, ketoconazole,
metronidazole), cancer agents (e.g., alkylating drugs),
cardiovascular drugs (e.g., amiodarone, captoptil, digi-
toxin), and psychoactive drugs (e.g., diazepam, halo-
peridol, phenothiazines, tricyclic antidepressants) have
been identified as possible hormonal mimics for the es-
trogen and androgen receptors (3). The mechanism by
which those drugs disrupt the endocrine system are less
well defined but could also involve altering steroido-
genesis, with a resultant change in the balance between
testosterone and estradiol (E2) levels, increasing pro-
liferation of breast tissue and leading to the onset of gy-
necomastia (3, 8). Previous clinical cases have established
a link between hygiene-product use of lavender oil (LO)
and tea tree oil (TTO) and prepubertal gynecomastia in
boys (8). However, to our knowledge, there are no
confirmed cases of such a link in prepubertal girls nor
identification of the active components.
LO is the most widely used essential oil by both men
and women (9). Some of the most important constitu-
ents in LO are linalyl acetate (LinA) and linalool (Lin)
(10). TTO is the third most popular essential oil used
today (9). Some of the most important constituents in
TTO are a-terpinene (a-Terp) and g-terpinene (g-Terp)
(11). Eucalyptol (Euc), 4-terpineol (4-Terp), dipentene/
limonene (Di/Lim), and a-terpineol (a-Terpl) are common
to both LO and TTO. All eight chemicals are mandated by
the International Organization for Standardization (ISO)
to be included in either LO or TTO (11, 12).
ERa plays a crucial role in mammary gland devel-
opment. This finding was confirmed from the phenotypes
of aromatase knockout mice that lack endogenous es-
trogen production and ERa knockout mice that lack
functional ERa. Both models exhibit impaired mammary
gland development (13), which supports the view that
estrogen-dependent, ERa-mediated actions are critical
for mammary gland development (14–17).
The lack of breast development observed in mice can
be extended to patients with clinical cases of aromatase
deficiency or ERamutations (2, 18). In another example,
an aromatase transgenic ERa knockout mouse had
significantly impaired mammary gland growth even
when high levels of endogenous estrogen were present
in the tissue (17), thus indicating that ERa-mediated
mechanisms are important in mammary gland develop-
ment as well as stimulation of mammary hyperpla-
sia in aromatase transgenic mice (14–17). Even more
interesting, in breast tissue, estrogens including the en-
dogenous hormone E2 regulate growth, cellular dif-
ferentiation, and physiological functions through ERa
(19–21). The receptor belongs to the nuclear receptor
(NR) superfamily of ligand-inducible transcription fac-
tors (22). The receptor exhibits distinct tissue-specific
expression patterns and biological roles (23). The an-
drogen receptor (AR) is also present in normal breast
tissue. The AR is a ligand-dependent nuclear transcrip-
tion factor and a member of the steroid nuclear receptor
family. Transcriptional coregulators are the principal
factors influencing gene expression in which they directly
interact with and modulate the activity of almost all NRs
and transcription factors (24, 25). Steroid receptor
coactivators (SRCs) were the first of the gene families to
be classified as coregulators for NRs. All members can
effectively enhance transcriptional activity of NRs by
acting as bridging molecules and assist with chromatin
modifications involving protein-protein interactions be-
tween NRs (24, 25).
An endocrine-disrupting chemical (EDC) is an exog-
enous chemical, or mixture of chemicals, that can in-
terfere with any aspect of hormone action (26). Some
EDCs act through nuclear hormone receptors (27), and
LO and TTO have been reported to potentially act as an
EDC in prepubertal boys (8). However, the mechanisms
by which these essential oil components act remain un-
clear. In this study, we report three cases of prema-
ture thelarche associated with exposure to essential oils
and a case of prepubertal gynecomastia. We studied
the mechanism of action of LO, TTO, and eight com-
ponents that are mandated to be included in essential oil
products, to determine their abilities to mimic estrogen
and androgen.
Materials and Methods
Study design
Case studies were performed at Nicklaus Children’s Hos-
pital and the Pediatric Endocrinology Clinic at the University of
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California, Irvine. All participants were selected on the basis of
eligibility. To be eligible for this study, patients had to be
prepubertal and continuously exposed to an essential-oil
product. No institutional review board approval was needed
to report these case studies. All participants were informed that
information regarding their case potentially would be compiled
for publication. Consent of the patient and their parents is
recorded in each patient’s medical chart. All mechanistic in vitro
experiments were performed at the National Institute of En-
vironmental Health Sciences.
In vitro studies
We used a variety of human cell models to characterize
the estrogenic and antiandrogenic activities of the essential oil
components. All models were performed at least three times
and all data reported from the experiments are averages of at
least three data sets with the exception of the reporter assays,
which are a representation of one data set from three others
performed.
Plasmids
The expression vector pcDNA3 was purchased from Invi-
trogen. An internal control plasmid for transfection efficiency,
Renilla luciferase, was purchased from Promega. The luciferase
reporter 3xERE Luc (synthetic vitellogenin ERE-TATA fused
to a luciferase reporter gene) have been described previously
(28). The pcDNA/ERa and pcDNA/SRC-2 plasmid have been
reported previously (25, 28).
Cell culture
The human breast cancer MCF-7 cell line (ERa positive)
and human hepatocellular cancer HepG2 cell line (ERa
negative) were purchased from American Type Culture
Collection. The human breast cancer MDA-kb2 cell line (AR
positive), stably expressing the MMTV promoter, has been
described previously (29). MCF-7 cells were maintained in
phenol red-free DMEM:F12 medium, HepG2 cells were
maintained in MEM medium, and MDA-kb2 cells were
maintained in Leibovitz’s medium (Invitrogen). All media
were supplemented with 10% fetal bovine serum (FBS;
Gemini Bio Products) and 4 mM L-glutamine (Invitrogen).
Charcoal/Dextran stripped fetal bovine serum (sFBS,
HyClone; Gemini Bio Products) was substituted for FBS during
treatment.
Chemicals and components
The E2, flutamide (Flut), LO (CAS no. 8000-28-0; prod-
uct no. 61718), TTO (CAS no. 68647-73-4; product
no. W390208), Euc, 4-terpineol (4-Terp), dipentene/limonene
(Di/Lim), a-Terpl, LinA, Lin, a-Terp, g-Terp, corn oil, and
soybean oil were purchased from Sigma-Aldrich. Testosterone
was purchased from Steraloids and fulvestrant/ICI 182,780
(ICI) was purchased from Tocris Bioscience. All essential oils
and their components were naturally extracted from their
source according to Sigma-Aldrich protocols. A mixture of the
components was used in similar percentages mandated by the
ISO to be included in LO and TTO. These are represented as LO
components (LO-Cs) and TTO components (TTO-Cs) and
were compared with LO and TTO for estrogenic activity.
Details concerning the selection of the eight components and the
mixture percentages are listed in Table 1. All components and
oils used in this experiment were diluted in dimethyl sulfoxide
(DMSO) and the vehicle control contained a final concentration
of DMSO not exceeding 0.1%.
Selection of components
LOandTTOeach containsmany diverse chemicals that vary in
structure and composition (10–12). Predicting whether a sub-
stance could potentially be an EDC is difficult, because these
components are diverse and may not appear to share any struc-
tural similarity other than having small molecular masses (27).
Stereochemistry was taken into consideration to observe if any
biological changes occurred between isomers. A variety of com-
pounds were chosen on the basis of chemical structures. These
parameters included if the compounds contained rings or no rings,
single bonds or double bonds, or if isomers of the same compound
made a difference in biological activity . Knowing information
about stereochemistry may be useful in predicting how other
chemicals in essential oils may behave that were not tested.
The ISO mandates that 13 and 14 components must be in
certain percentage ranges to be classified as LO or TTO, re-
spectively. Common chemicals observed between LO and TTO
are Euc, 4-Terp, Di/Lim, and a-Terpl (11, 12, 30–32).
Chemicals specific to either oil were also chosen. LO by con-
centration can contain #92% LinA and Lin by volume (33),
and these two components are most likely what gives LO its
specific smell. To further justify choosing these two chemicals,
literature shows that experiments have been performed pre-
viously with the chemical Lin (34). The two chemicals selected
specific to TTO were a-Terp and g-Terp, which are also found
in relatively high percentage in TTO (11).
Table 1. Selected Components From LO and TTO
Component CAS RN % Purity Essential Oil % LO-C % TTO-C Sigma-Aldrich Catalog No.
Euc 470-82-6 $99 Both 2.8 13.2 W246506- Sample-K
4-Terp 562-74-3 $95 Both 7.5 42.3 W224847-Sample
Di/Lim 138-86-3 Mix of isomers Both 1 1.3 W524905-Sample-K
a-Terpl 10482-56-1 $96 Both 1.9 7.1 W304522- Sample-K
LinA 115-95-7 $97 LO 44.3 — W263605- Sample-K
Lin 78-70-6 $97 LO 42.5 — W263508-Sample-K
a-Terp 99-86-5 $89 TTO — 11.4 W355801-Sample-K
g-Terp 99-85-4 $95 TTO — 24.7 W355909-Sample-K
Abbreviation: CAS RN, Chemical Abstracts Service registry number.
doi: 10.1210/jc.2018-01880 https://academic.oup.com/jcem 5395
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Luciferase reporter assays with ERa
HepG2 cells were seeded in MEM:F12 plus 10% FBS at 1.53
105 to 2.0 3 105 cells per well in 24-well plates overnight. The
medium was changed toMEM plus 10% sFBS the next day before
transient transfection using the Effectene transfection reagent
(Qiagen). A total of 0.5mg/well (3xERE luc, humanERa, and pRL-
TK plasmids) or 0.7 mg/well (SRC-2, vector pcDNA3, 3xERE luc,
human ERa, and pRL-TK plasmids) were transfected into the cells.
After 6 hours, the cells were changed to fresh MEM:F12 plus 10%
sFBS medium overnight and were treated with vehicle control
(DMSO); 1 nM E2; 0.005%, 0.01%, or 0.025% (v/v) LO, LO-C,
TTO, or TTO-C; or 100, 500, or 1000 mM Euc, 4-Terp, Di/Lim,
a-Terpl, LinA, Lin, a-Terp, or g-Terp for 18 hours.
Luciferase reporter assays were performed using the Dual
Luciferase Reporter Activity System (Promega) and an LMAX
II luminometer (Molecular Devices). Transfection efficiency
was normalized using the Renilla luciferase pRL-TK plasmid
and fold changes were calculated relative to the vehicle control.
Calculations for appropriate concentrations to treat the cells
were extrapolated from our previous report (8) and from the
data repository (35). Relative percentages of the individual
components in reference to LO and TTO were provided by the
ISO. These percentages were back calculated to find a range of
molarity in which they could be hormonally active.
Two-hybrid mammalian ERa ligand binding affinity
assay with SRC2
To evaluate the binding activity of the oil components to the
ERa ligand-binding domain (LBD), we performed a mammalian
two-hybrid assay, which analyzes the ligand dependency of hERa
LBD and SRC-NR element interactions (36).We selected SRC-2-
NR for this assay because overexpression of SRC-2 inHepG2 cells
enhanced ERa-mediated transcription activity for all chemicals,
which is shown in Fig. 1B. A total of 0.3mg/well [Gal4-DBD-fused
SRC-NR-box (pM-SRC-NR), VP16-AD (pACT), or VP16-AD-
fused-ERa WT-LBD (pACT-LBD/WT), and pRL-TK plasmids]
were transfected into the cells (37). After 6 hours, the cells were
changed to fresh MEM plus 10% sFBS medium overnight and
were treatedwith vehicle control (DMSO); 1 nME2; 0.025% (v/v)
LO, LO-C, TTO, or TTO-C; or 500 mM Euc, 4-Terp, Di/Lim,
a-Terpl, LinA, Lin, a-Terp, or g-Terp for 18 hours. Luciferase
assays were performed using the Dual Luciferase Reporter Assay
System. Transfection efficiency was normalized using the Renilla
luciferase pRL-TK plasmid and fold changes were calculated
relative to the vehicle control. Experimental transfection condi-
tions can be found in the data repository (35).
Treatment, RNA isolation, and quantitative
PCR analysis
MCF-7 (ERa-positive) and MDA-kb2 cells (AR-positive)
were selected to measure gene changes. For ERa target genes,
MCF-7 cells were seeded in six-well plates at 500,000 cells per
well in DMEM:F12 plus 10% FBS medium overnight. The cells
were then starved in phenol red-free DMEM:F12 plus 5% sFBS
medium for 36 hours and treated with vehicle control (DMSO),
1 nM E2, 0.025% (v/v) LO or TTO, or 1000 mM Euc, 4-Terp,
Di/Lim, a-Terpl, LinA, Lin, a-Terp, or g-Terp for 18 hours,
with or without 5 mM ICI. For AR target genes, MDA-kb2 cells
were seeded in six-well plates at 750,00 cells per well in phenol
red-free Leibovitz’s medium plus 10% FBS medium. The cells
were then starved in phenol red-free Leibovitz’s medium plus
5% sFBS medium for 24 hours and treated with vehicle control
(DMSO), 1 nM T, and 1 nM testosterone plus 1 mM Flut for
controls. Cells also were cotreated with 1nM testosterone and
0.025% (v/v) LO or TTO, or 100 mM Euc, 4-Terp, Di/Lim,
a-Terpl, LinA, Lin, a-Terp, or g-Terp for 18 hours.
Total RNA was extracted from MCF-7 and MDA-kb2 cells
using the RNeasy Mini Kit (Qiagen). First-strand cDNA syn-
thesis was performed using Superscript reverse transcription
according to the manufacturer’s protocol (Invitrogen). The
mRNA levels of ERa target genes [Growth regulation by es-
trogen in breast cancer 1 (GREB1), progesterone receptor
(PGR), and cathepsin D (CTSD)] and AR target genes [cyto-
chrome P450 family 4 subfamily F member 8 (CYP4F8), UDP
glucuronosyltransferase family 2 member B28 (UGT2B28),
and SEC14-like lipid binding 2 (SEC14L2) were measured
using SYBR green assays (Applied Biosystems). Cycle threshold
values were obtained using the ABI PRISM 7900 Sequence
Detection System and analysis software (Applied Biosystems).
Each sample was normalized to human b-Actin expression and
fold changes were calculated relative to the vehicle control cycle
control values. The sequences of quantitative PCR primers used
in this study are shown in the data repository (35).
Luciferase reporter assays with AR
To examine transcriptional changes of AR, we investigated
promoter activation using the mouse mammary tumor virus
(MMTV), which contains an androgen response element, stably
transformed in the AR-positive MDA-kb2 cell line. Calculations
for appropriate dosing were extrapolated from our previous
report (8) and from calculations in the data repository (35).
Multiple dose curves were performed to find a range in which
these components activated the promotor MMTV. MDA-kb2
cells were seeded in 48-well plates at 100,000 cells per well in
phenol red-free Leibovitz’smediumplus 10%FBS overnight. The
medium was changed to Leibovitz’s medium 5% sFBS after 6
hours and starved for a total of 24 hours. Cells were treated with
the vehicle, 1 nM T, and 1 nM testosterone plus 1 mM Flut for
controls. To test the essential oils and their components, cells
were cotreated with 1 nM testosterone and 0.01% (v/v) LO or
TTO, or 0.1,1, 10, 100, and 1000 mM Euc, 4-Terp, Di/Lim,
a-Terpl, LinA, Lin, a-Terp, or g-Terp for 18 hours.
Statistical analysis
The data were analyzed using Tukey and Dunnett multiple
comparison tests in GraphPad prism, version 7.0 (GraphPad
Software, San Diego, CA). All statistical tests were considered
significant at P , 0.05. Any outliers that were identified were
excluded using a Grubb test in GraphPad, version 7.0.
Results
Case reports
A total of 24 patients with prepubertal gynecomastia
or premature thelarche have been seen at the Division of
Endocrinology at Nicklaus Children’s Hospital over the
past 7 years. Five girls with transient thelarche were
exposed to lavender-containing products, and breast
development resolved after removing lavender expo-
sure. Eleven of the 19 boys with prepubertal gy-
necomastia were exposed to products (e.g., colognes,
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shampoos, or soaps) containing lavender fragrance. Of
the 16 patients exposed to lavender, 14 were Hispanic,
one was Haitian, and one was white. The etiology of
prepubertal gynecomastia in the eight other boys was as
follows: The causes in three cases was undetermined
(idiopathic), three boys had aromatase excess deter-
mined by elevated serum estrogen levels, and two were
fed with soy milk for several years. Two of the patients
with aromatase excess were white and one was of Ar-
abic decent.
Four female patients have been seen at the Pediatric
Endocrinology Division at the University of California,
Irvine, and Children’s Hospital of Orange County’s clinic
with premature breast development. Of the four patients,
three were white and one was Middle Eastern. All pa-
tients had used lavender-fragrance products (e.g., soaps,
Figure 1. ERa ERE-mediated transcriptional activity, coactivator SRC-2 recruitment, binding to the ERa LBD, and ERa-regulated gene expression.
(A) Dose-dependent estrogenic responses of HepG2 cells. The cells were transfected with ERE-luciferase and human ERa expression plasmid
[plasmid cloning DNA (pcDNA)/ERa]. A Dunnett multiple comparison test was performed in comparison with the vehicle control. All experiments
were performed at least three times. Results are a representation of one experiment and are presented as mean 6 SEM. (B) SRC-2
transcriptional enhancement of HepG2 cells. The cells were transfected with human pcDNA/ERa plasmids, with or without pcDNA/SRC-2. Data
were normalized against each vehicle group. A Tukey multiple comparison test was performed in comparison with ERa and SRC-2 plus ERa
treatment groups. All experiments were performed at least three times. Results are an average of the experiments and are presented as mean 6
SEM. (C) Binding to the ERa-LBD in HepG2 cells. The cells were cotransfected with pG5-luciferase reporter plasmid and the expression plasmids
for the Gal4-DBD-fused SRC-2-NR-box (pM-SRC-2-NR) in the presence of VP16-AD (pACT) or VP16-AD-fused-ERa WT-LBD. Data were
normalized against each vehicle group and its respected pACT treatment group. A Dunnett multiple comparison test was performed in
comparison with vehicle control ERa-LBD. All experiments were performed at least three times. Results are an average of the experiments and
are presented as mean 6 SEM. (D) Induction of ERa endogenous genes and inhibition of induction when cotreated with the antagonist ICI in
MCF-7 cells. Total RNA was extracted and mRNA levels of GREB1, PGR, and CTSD genes were quantified by quantitative PCR analysis. All gene
fold changes were normalized against ACTB. Results are presented as mean 6 SEM. “a” Denotes statistical significance in comparison with
vehicle control, P , 0.05; and “b” denotes statistical significance in comparison against each treatment group, with or without the addition of
ICI, P , 0.05. (A–C) *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. Luc, luciferase.
doi: 10.1210/jc.2018-01880 https://academic.oup.com/jcem 5397
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lotions, essential oils), but then stopped after visitation to
the clinic. Two patients’ conditions resolved since stop-
ping use and the other two patients have developed
symptoms of precocious puberty.
Patient 1
A girl 7 years and 6 months old presented for addi-
tional evaluation after initial observation of a left breast
bud at age 6 years. Her past medical history was un-
remarkable, and she was taking no medication. Her
family history was noncontributory. She was of normal
height and weight for her age. Breast tissue growth was
observed by physical examination on the left side mea-
suring 4 cm3 3 cm in size and no breast tissue growth on
the right side. Pubic hair was Tanner stage 1 and her
clitoris was normal. Laboratory tests showed the fol-
lowing prepubertal gonadotropin levels: LH, 0.01 mIU/
mL; FSH, 0.319 mIU/mL; E2, ,1 pg/mL. Thyroid
function tests were normal. Bone age corresponded to her
chronological age. On further questioning, the family
noted the patient’s frequent exposure to lavender oil in
the form of a cologne named “Mi Tesoro Agua de
Violetas” since early childhood. Breast development
resolved 6 months after discontinuing use of the cologne
with no recurrence upon follow-up.
Patient 2
A girl 3 years and 11 months old had right-side breast
development at age 1 year that was observed by her
mother. The patient complained of 2 months of breast
tenderness at 3 years of age and was evaluated by a
pediatrician. Her mother reported that she had been
bathed with a soap containing lavender oil named “Baby
Magic Calming Baby Bath Lavender and Chamomile”
since infancy. Her past medical history was unremark-
able, and she was taking no medications. Upon physical
examination, she had breast tissue growth on the right
side measuring 3 cm3 3 cm. Her pubic hair was Tanner
stage 1 and her clitoris was normal. A breast ultrasound
confirmed the presence of breast ductal development
measuring 3.28 cm3 2.8 cm in size and 1.12 cm in depth.
Her bone age was within the normal range for her
chronological age. Total resolution of her breast tissue
was noted 6 months after discontinuation of the soap
containing lavender oil.
Patient 3
A girl 7 years and 9 months old had a left breast bud
without other signs of puberty. She informed the phy-
sician that she sat near a teacher’s table, which had a
lavender-oil diffuser running all day and was exposed to
lavender oil for 1 year before noticing breast develop-
ment. Her height and weight were normal for her age.
Her physical examination was positive for left sub-
areolar breast tissue, Tanner stage 2; and pubic hair
of Tanner stage 1. Pelvic ultrasound showed a uterus
that was enlarged to the peripubertal size with a thin
endometrial stripe of 0.07 cm and prepubertal ova-
ries. Her bone age corresponded to her chronological
age. Exposure to lavender oil was discontinued and
her breast tissue completely regressed upon evaluation
3 months later.
Patient 4
A boy 7 years and 11 months old had breast en-
largement at 4 years of age. Hewas taking nomedication.
Since infancy, he was exposed daily to lavender oil named
“Crusellas Violet Water cologne.” His past medical
history was positive for attention deficit and speech
delay, but he required no medication. His height and
weight were above the percentiles that corresponded to
his age; however, his body mass index was at the 95th
percentile for age and sex. Upon physical examination, he
demonstrated bilateral breast development measuring
43 4 cm in size and 3 cm in depth, and bilateral testicular
volume of 1 mL. He had a previous chromosomal
microarray, which was normal. His gonadotropin levels
were prepubertal (LH, 0.01 mIU/mL; FSH 0.67 mIU/mL)
and testosterone was 4.8 ng/dL. His level of estrogens
(E2, 1.1 pg/mL; estrone, 20 pg/mL), 17-hydrox-
yprogesterone (77 ng/dL), and prolactin (12 ng/mL) were
all normal for his age and sex. His bone age was within
the normal range for his chronological age. Resolution of
his breast tissue was noted 6 months after discontinua-
tion of the cologne and there was no further recurrence.
Of note, these children were not genetically related to
each other.
ERa estrogen response element–mediated activity
To determine if there were direct dose-dependent es-
trogenic responses of LO and TTO components, we
transfected HepG2 cells with human ERa and three
copies of estrogen response elements (EREs) to in-
vestigate ERa ERE-mediated promotor activity. When
the cells were treated with 1 nM E2, almost a 50-fold
ERa ERE-mediated promotor activity was observed
when compared with nontreated cells (35). LO and
TTO showed significant activation at all concentrations
(0.005%, 0.01%, and 0.025%), with a maximum at
;20-fold ERa ERE-mediated promotor activity increase
for both oils (35). To test the activities of LO and TTO
components for comparison with natural LO and TTO,
components were reconstituted and mixed (designated as
LO-C and TTO-C). Significant activation of LO-C and
TTO-C was observed at all concentrations, except
0.005% TTO-C. The highest fold changes observed for
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these mixtures were approximately 10-fold, with TTO-C
being the greatest (35).
When comparing the individual oil components that
are common between LO and TTO, a-Terpl had the
highest ERa ERE-mediated promotor activity increase in
activation at all concentrations, with approximately
sixfold increase at 500 mM and greater than an eightfold
increase at 1000 mM (Fig. 1A). The second most potent
compound was 4-Terp, which had a twofold increase at
100 mM, a fourfold increase at 500 mM, and an almost
eightfold increase at 1000 mM (Fig. 1A). Di/Lim showed
no activation at any concentrations except with almost a
twofold increase at 1000 mM (Fig. 1A). Euc was inactive
and showed no significant activation at any concentra-
tion (Fig. 1A). Of the components specific to LO, Lin was
the most potent at all concentrations, with more than a
twofold increase at 100 mM, a sixfold increase at
500 mM, and an almost eightfold increase at 1000 mM.
LinA showed a modest twofold increase at 500 mM and
fourfold increase at 1000 mM, but LinA showed no
activation at 100 mM (Fig. 1A). TTO components,
a-Terp and g-Terp, showed no significant induction at
any concentrations except for g-Terp , which was in-
creased threefold at 1000 mM (Fig. 1A). These findings
are summarized in Table 2 and indicate that some, but
not all, individual components in LO and TTO showed a
dose-dependent transcriptional enhancement of ERa
activity$100 mMwith maximum fold change of$20%
of E2.
ERa ERE-mediated activity with SRC-2
To determine if the ERa ERE-mediated transcrip-
tional regulation by the components and oils were
modulated by specific coactivators, HepG2 cells were
cotransfected with SRC-2 and ERa expression plasmid.
Significant induction of ERa ERE-mediated activity
occurred with 1 nM E2 and 0.01% (v/v) LO and TTO
(35). However, when components of LO and TTO were
tested, there was specific SRC-2 selectivity. 4-Terp,
a-Terpl, LinA, and g-Terp were the only components
that significantly activated ERa ERE-mediated activity
with the addition of SRC-2 (Fig. 1B). These findings
suggest that certain components in LO and TTO can
effectively and selectively recruit SRC-2 and increase the
transcriptional activation in the ERa-ligand complex.
Coactivator recruitment and functional ER a
ligand binding
HepG2 cells were cotransfected with pG5 luciferase
and pM-SRC-2-NR (SRC-2 NR box) in the presence of
VP16-AD pACT or pACT-LBD/WT to determine the
ability of ligands to bind to the receptor and initiate
recruitment of SRC-2 to the ERa LBD (Fig. 1C). The
positive control, 1 nM E2, recruited SRC-2 NR box and
demonstrated binding to the LBD of ERa (35). In ad-
dition, 0.01% LO, LO-C, and TTO showed recruitment
of SRC-2 NR box and demonstrated binding to the LBD
of ERa. Studies with components common and specific
between LO and TTO demonstrated selective ability to
recruit SRC-2 to the ERa LBD. Only three of the com-
ponents (a-Terpl, LinA, and Lin) showed significant
activity dependent on binding to the LBD of ERa and
recruitment of the SRC-2 NR box (Fig. 1C). These
findings indicate that some of the selected components in
LO and TTO can bind to the LBD of ERa and effectively
recruit SRC-2.
ERa-regulated gene expression
To determine the activity of the components in reg-
ulating endogenous genes, we characterized the ERa-
dependent responses of LO and TTO components by
examining three well-known ERa regulated genes:
GREB1, PGR, and CTSD (28). MCF-7 breast cancer
cells were treated with 1 nM E2, 0.025% (v/v) LO or
TTO, and 1000 mM of the eight components, with or
without the ERa antagonist ICI, and quantitative PCR
was performed. All three genes showed significant in-
duction when treated with E2, LO, and TTO, and were
blocked when cotreated with ICI, the ERa antagonist.
The only exception was the lack of LO activity for PGR
Table 2. Summary of Estrogenic Activity of LO and
TTO Components
Reporter Assaya
ERa-Regulated
Genesb
Treatment
ERa ERE-Mediated
Activityc GREB1c PGRc CTSDc
E2d 100 100.0 100.0 100.0
LO 17.0 17.9 8.3 101.3
TTO 17.9 22.6 12.7 90.2
Euc 3.0 10.4 8.1 87.6
4-Terp 15.4 13.8 10.6 94.2
Di/Lim 4.0 11.0 13.3 82.7
a-Terpl 17.6 8.0 5.5 82.2
LinA 8.0 12.9 9.2 86.7
Lin 15.7 14.1 9.6 88.0
a-Terp 3.1 10.9 8.7 76.4
g-Terp 5.1 8.1 9.4 80.9
Data are reported as %.
aData summarized from Fig. 1A and data repository (35).
bData summarized from Fig. 1D and data repository (35).
cHigher percentages indicate stronger estrogenicity and smaller per-
centages indicate weak estrogenicity.
dE2 activation was set to 100% and percent change in activity was
calculated relative to twofold change for LO, TTO, and the eight
components.
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stimulation (35). GREB1 showed significant induction
with all eight components (Fig. 1D). In addition, sig-
nificant GREB1 gene induction was inhibited by ICI
with all treatments (Fig. 1D). Induction of the PGR gene
was more selective than GREB1 induction. Treatment
with 4-Terp, Di/Lim, LinA, Lin, and g-Terp showed
significant PGR gene upregulation, and that induction
was significantly blocked when cotreated with ICI
(Fig. 1D). As for CTSD, all components induced sig-
nificant upregulation. ICI reduced CTSD induction for
all components except a-Terp and g-Terp (Fig. 1D).
These findings indicate that differential gene responses
are seen from stimulation by select components in LO
and TTO. This group of ERa-regulated genes was
blocked by ICI, but the inhibition was individualized
and not common across all components and genes
(Fig. 1A-D).
AR MMTV-mediated activity
Previously, we reported a unique property of LO and
TTO that showed antiandrogenic activities in vitro (8).
To test this further, the AR-positive MDA-kb2 cell line
stably expressing an MMTV promotor reporter con-
struct was used to investigate AR MMTV-mediated
activity by the oils and their components. Cells had a
positive response to 1 nM testosterone with a three- to
fourfold increase and that response was significantly
blocked when cotreated with the AR antagonist
Flut (35). Increasing dose of LO and TTO signifi-
cantly inhibited AR MMTV-mediated activity at all
concentrations $0.0005% (v/v) when cotreated with
testosterone (35).
We then investigated the single oil components that
may be responsible for that activity. Three of the four oil
components common between LO and TTO significantly
decreased fold activation compared with 1 nM testos-
terone, to the level comparable to 1 mM Flut, a known
antiandrogen (Fig. 2A). 4-Terp and a-Terpl showed a
significant decrease in AR MMTV-mediated activity
at concentrations $1 mM. Di/Lim was not as potent
and significantly reduced AR-MMTV mediated activity
at $10 mM. Euc showed no activity or significant re-
duction in AR MMTV-mediated activity at any of the
concentrations (Fig. 2A).
The components specific to LO, Lin and LinA, showed
inhibition of AR MMTV-mediated activity at $1 mM
or$100 mM,with Lin having the more complete efficacy
of $1 mM (Fig. 2A). The TTO components reduced AR
MMTV-mediated activity at 100 and 1000 mM only,
with g-Terp being more highly effective than a-Terp
(Fig. 2A). These findings are summarized in Table 3 and
indicate that the selected individual components in LO
and TTO can inhibit transcriptional activity of the AR.
AR-regulated gene expression
To test if AR-regulated endogenous gene responses
were also inhibited by LO and TTO components, we
examined three well-known AR-target genes:SEC14L2,
CYP4F8, andUGT2B28. Gene expression wasmeasured
using quantitative PCR in treated MDA-kb2 cells (8). All
data were normalized againstACTB and are presented in
Fig. 2B. The controls, testosterone plus Flut, testosterone
plus LO, and testosterone plus TTO, all significantly
blocked SEC14L2, CYP4F8, and UGT2B28 (35).
All eight components showed significant inhibition of
testosterone-stimulated SEC14L2 expression (Fig. 2B).
However, inhibition of CYP4F8 was more selective than
SEC14L2. 4-Terp, Di/Lim, a-Terpl, LinA, Lin, and
g-Terp significantly blocked CYP4F8 induction, but
Euc and a-Terp showed no antiandrogenic effects on
CYP4F8. UGT2B28 was the most selective of the three
genes examined. 4-Terp, a-Terpl, LinA, and Lin were the
only components that showed significant inhibition of
induction of UGT2B28, whereas Euc, Di/Lim, a-Terp,
and g-Terp showed no antiandrogenic effects on
UGT2B28 (Fig. 2B). These findings demonstrate that
some of the essential-oil components demonstrate dif-
ferential antiandrogenic properties of AR-regulated
genes.
Discussion
Premature thelarche and prepubertal gynecomastia are
secondary to precocious puberty or to abnormal pro-
duction of sex hormones before the normal age. The-
larche and pubarche are considered normal after age
8 years. Menarche is considered normal after age 9 years
in girls and gonadarche is considered normal after age
9 years in boys (38). Approximately 40% to 60% of boys
develop pubertal gynecomastia after age 9 years, which is
considered normal (7). However, over the past decade,
the onset of puberty has been reduced to younger ages by
12 to 18 months (39). EDCs have been well accepted for
their ability to modulate the endocrine system (39).
Therefore, it has been thought that environmental ex-
posures could be considered as a possible cause of these
conditions (39). Topical applications of LO and TTO
have been linked previously to prepubertal gynecomastia
in boys, but such a condition in girls has not been re-
ported, to our knowledge (7, 8).
In this study, we describe the development of pre-
mature thelarche in three girls and a case of prepubertal
gynecomastia in one boy. The continuous use of LO-
fragrance products was common across these clinical
cases, and in all cases, breast tissue regressed when oils
were discontinued. Other possible considerations should
be mentioned for these clinical conditions. Apart from
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LO and TTO components, commercial products con-
taining essential oils could possess ingredients that have
EDC effects. Consideration of other active ingredients
is difficult, because most commercial over-the-counter
products have minimal ingredient listings. Therefore, we
could only assume that products labeled as containing
LO followed ISO regulations and did contain the com-
ponents that were relevant to the components we tested.
Transient thelarche, a clinically reported condition that
can subside on its own, might be another explanation for
the breast tissue resolving. Thus, the resolving of the
patient’s condition could have been coincidental in
timing to the discontinuation of the suspected essential-
oil products.
Fragranced products are used at higher rates in
Hispanic communities than other ethnicities (e.g., the
product agua) (40). Diaz et al. (7) reported HPLC–mass
spectrometry analysis of the aqua de violetas product,
which detected the presence of Lin and LinA, as well as
unidentified substances. These two components of LO
were analyzed in our study and both showed anti-
androgenic and weak estrogenic activity. The associa-
tion between LO-containing products and premature
thelarche and prepubertal gynecomastia appear to be
more prevalent in Hispanic populations, based on ob-
servations in our clinic. Premature thelarche may not
have been reported previously because of relatively high
prevalence of idiopathic breast development in girls
compared with boys and the high rate of regression (4,
5). We speculate that another possible explanation for
the high prevalence in the Hispanic population could be
due to a genetic polymorphism resulting in sensitivity
to the essential oils or other components. Additional
studies would be required to determine if such a genetic
Figure 2. AR MMTV-mediated transcriptional activity and AR-regulated gene expression. (A) Dose-dependent antiandrogenic responses of MDA-
kb2 cells when cotreated with testosterone (T). A Dunnett multiple comparison test was performed in comparison with 1 nM T. All experiments
were performed at least three times. Results are a representation of one experiment and are presented as mean 6 SEM. (B) Antiandrogenic
responses of endogenous genes in MDA-kb2 cells when cotreated with T. Total RNA was extracted and mRNA levels of the genes SEC14L2,
CYP4F8, and UGT2B28 were quantified by quantitative PCR analysis. All gene fold changes were normalized against ACTB. A Dunnett multiple
comparison test was performed in comparison with 1 nM T. All experiments were performed at least three times. Results are an average of the
experiments and are presented as mean 6 SEM. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. Luc, luciferase.
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susceptibility exists associated with exposure to these
products.
Multiple studies have focused on exposure rates of
these essential oils frommany personal care products and
cosmetics (9, 41). A study examined skin exposures of
essential oils between men and women. There were
differences between the areas of the body to which the
essential oils were most commonly applied between men
and women. The chest/breast area was the most com-
monly applied area on the body of men (64%), whereas
the face/neck area was highest in women (71%), and
were both statistically significant from the other sex.
When comparing exposures, LO was the most used es-
sential oil by men and women (9). Such clinical findings
could be another explanation of why topical exposure to
essential oils and the development of prepubertal breast
growth is seen at higher rates in boys than in girls.
Previous studies have demonstrated that dermal ex-
posure to essential oils results in circulating concentra-
tions that are comparable to the concentrations used in
vitro (42, 43). In contrast, an industry-supported ex-
perimental study reported percutaneous exposure of LO
showed no uterotropic estrogenic activity (44). An ad-
ditional report indicated no estrogenic activity in a yeast
assay using Lin (45). The discrepancies in such findings
are likely directly related to differences in experimental
approaches used between the studies. An assumption that
percutaneous dorsal exposure would produce an utero-
tropic action revolves around the assumption that suffi-
cient absorption of the LO fragrance would become
systemic to produce a distant tissue estrogen effect. The
primary method to test uterine estrogenic activity is
principally done either by ingestion or injection. In one
study, the comparative positive control used gavage of
17a ethynyl estradiol (44). The treatment schemes were
quite different between the two groups, although it would
have been a directly testable exposurewith a fully accepted
target end point if found positive (44). On the other hand,
in our cases, the patients’ suspected area of exposure,
which was the breast area, was in direct contact with the
essential oil and not at a distant site. We were unable to
determine the circulating concentrations of components of
essential oils in these children. However, it is important to
note that exposure to directly affected areas was contin-
uous over month-long periods in each case. Moreover, the
specific compounds are lipophilic and even low-dose ex-
posures would be expected to result in some accumulation
in the breast and associated adipose tissue sites (27).
Continuous early-age exposures with other substances
have been reported with EDC effects (46, 47).
Essential-oil components have not been previously
classified as EDCs, but our current data provide evidence
that these components have properties that match the
definition of an EDC (26, 27). We confirmed that both
LO and TTO contain components that antagonize AR
transcriptional activity and weakly induce ERa gene
responses, although we found that not all components
are hormonally active. Lower transcriptional activation
was observed in the composed mixtures vs the natural
LO and TTO product mixtures. These differences may
indicate that there could be other components or sub-
stances present in the essential oils that also possess es-
trogenic activity or act synergistically with other EDCs,
to explain the observed differences (48).
The estrogenic and antiandrogenic effects of the es-
sential oil components are summarized in Tables 2 and 3.
Overall, the oils and their components appear experi-
mentally to have greater potency as antiandrogens than
as estrogens. Interestingly, components that had stron-
ger estrogenicity also demonstrated the strongest anti-
androgenic properties. Antiandrogenic activity is not
directly linked to breast stimulation, although the anti-
androgenic action of the essential oils would be more
relevant to blocking the natural action in boys than girls,
in whom androgens inhibit breast development (49). As
shown previously (7), the activity would be most effective
in the presence of low endogenous androgen levels (e.g.,
prepubertal boys) than those of adolescents or adults
with higher postpubertal androgen levels. Moreover, the
Table 3. Summary of Antiandrogenic Activity of
LO and TTO Components
Reporter
Assaya,b AR Regulated Genesc
Treatment
AR MMTV-
Mediated
Activity CYP4F8 UGT2B28 SEC14L2
Td 100.0 100.0 100.0 100.0
T 1 Flut 54.4 10.3 18.8 14.3
T 1 LO 37.0 4.5 17.5 13.7
T 1 TTO 35.9 5.5 20.5 14.0
T 1 Euc 90.0 143.7 80.0 68.7
T 1 4-Terp 26.4 64.4 54.1 43.3
T 1 Di/Lim 75.7 38.9 98.7 57.2
T 1 a-Terpl 12.3 6.0 28.8 16.8
T 1 LinA 72.7 36.3 46.7 29.6
T 1 Lin 46.1 20.1 34.1 24.2
T 1 a-Terp 74.1 104.8 100.1 79.6
T 1 g-Terp 39.1 51.0 102.7 78.8
Data are reported as %.
Abbreviation: T, testosterone.
aData summarized from Fig. 2A and data repository (35).
bSmaller percentages indicate stronger antiandrogenicity and larger
percentages indicate weaker antiandrogenicity.
cData summarized from Fig. 2D and data repository (35).
dTestosterone activation was set to 100% and percent change in activity
was calculated relative to testosterone fold-change for LO, TTO, and the
eight components.
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same relationship between the strengths of estrogenicity
and antiandrogenicity are also seen with other well-
known EDCs, such as bisphenol A (BPA) and bisphe-
nol AF (27, 48, 50). Most detrimental actions of
hormonally active agents have been linked to very po-
tent substances (e.g., diethylstilbestrol). Whether the
lavender-fragrance components have sufficient potency
to elicit the effects is impossible to test because intentional
dosing with essential-oil components is untenable. The
level of activity of the more active components, as re-
ported from the experimental data in Table 2, is similar
to that of estriol, the natural weak estrogen (51, 52).
Experimentally, it has been shown that persistent ex-
posure to estriol results in comparable activity and re-
sponsiveness as to estradiol (53, 54). One possible
explanation is that although weaker in potency, the
localized and persistent exposure or application to
the essential-oil fragrance may result in developing the
condition, especially in individuals of high sensitivity.
Additional studies will have to be conducted to test this
possibility.
Coactivators, including SRC-2, are a critical compo-
nent needed to execute the many sub steps of tran-
scription involving NRs and modulate the magnitude of
transcriptional responses (25, 55). We showed that LO,
TTO, and certain components had enhanced ERa
transcription with the addition of SRC-2, suggesting that
the selected components actions in vivo could be more
potent hormonal mimics than demonstrated in vitro,
because SRC-2 is present in humans (24, 55). More in-
terestingly, in the functional two-hybrid assay, LO, TTO,
and select components bound to the LBD of ERa showed
recruitment of SRC-2. Some of the components that
displayed stimulation of ERa transcription with addition
of SRC-2 showed no recruitment of SRC-2 and binding
to the ERa-LBD. It is unclear why this discrepancy oc-
curs, but we previously reported that EDCs, such as BPA,
can selectively bind to certain SRC binding motifs, but
not other motifs (28). The current two-hybrid binding
system used in the current has certain limitations because
it is composed of only two binding motifs compared with
multiple other motifs present on the full-length SRC-2
(37). Therefore, our assay used only two motifs of the
SRC and it is possible that the biological activity was a
result of recruitment of another motif. Thus, this may
explain why only a few components bound to the ERa-
LBD but still showed significant induction when tested
with full-length SRC-2 overexpression. A larger and
broader coactivator screen, as used previously (28),
would need to be done to test this possibility.
Earlier speculation raised questions regarding an
earlier report (8) as to whether the properties of an oil in
general could dissolve BPA analogs from the plastic assay
plates and, therefore, elicit the detected hormonal activity
(56).We addressed this concern by conducting additional
experiments with corn and soybean oil alongside LO and
TTO. Shown in the data repository (35), LO and TTO, as
well as some of their individual components, had es-
trogenic activity, but corn and soybean oil had no de-
tectable activity.
In summary, we have shown regression of pre-
mature thelarche in addition to pubertal gynecomastia
after withdrawal of lavender-fragranced products. We
have also measured the hormonal activity of select
essential-oil components and their spectrum of ER and
AR activities. Taken together, it is important that
physicians are aware that LO and TTO possess EDC
activities that should be considered in the evaluation of
premature breast development in girls and gyneco-
mastia in boys and adult men. We are not recom-
mending any avoidance of these products; rather, we
are suggesting that essential-oil products may be
considered for discontinuance if suspected to be a
possible cause of idiopathic premature thelarche or
prepubertal gynecomastia.
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